{"id":"609a","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown adverse event"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of 609A is not well understood, but it is believed to work by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"609A is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:27:17.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown indication"}]},"trialDetails":[{"nctId":"NCT03538626","phase":"PHASE1","title":"Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-21","conditions":"HIV Antibodies","enrollment":33},{"nctId":"NCT05193214","phase":"PHASE2","title":"A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2022-01-25","conditions":"Sarcoma, Soft Tissue","enrollment":30},{"nctId":"NCT05138146","phase":"PHASE2","title":"A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2021-12-30","conditions":"Sarcoma, Soft Tissue","enrollment":70},{"nctId":"NCT03998345","phase":"NA","title":"Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2020-07-25","conditions":"Solid Tumors","enrollment":24},{"nctId":"NCT03950297","phase":"PHASE1","title":"Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2019-05-01","conditions":"Solid Tumors","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"609A","genericName":"609A","companyName":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","companyId":"sunshine-guojian-pharmaceutical-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"609A is a small molecule drug that targets the molecular target. Used for Unknown indication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}